T Reffelmann

Summary

Country: Germany

Publications

  1. ncbi Low serum magnesium concentrations predict cardiovascular and all-cause mortality
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17487 Greifswald, Germany
    Atherosclerosis 219:280-4. 2011
  2. ncbi Images in cardiovascular medicine. Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy
    Thorsten Reffelmann
    Medical Clinic I, Department of Cardiology, University Hospital Aachen, , Pauwelsstrasse 30, 52057 Aachen, Germany
    Circulation 114:e357-8. 2006
  3. ncbi Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B Ernst Moritz Arndt Universität Greifswald, Greifswald, Germany
    Expert Opin Pharmacother 8:965-74. 2007
  4. ncbi The cardiovascular safety of tadalafil
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinik der, Ernst Moritz Arndt Universitat Greifswald, Friedrich Löffler Str 23 a, 17475 Greifswald, Germany
    Expert Opin Drug Saf 7:43-52. 2008
  5. ncbi Unintentional extraction of a coronary stent deployed 4 months earlier during cutting-balloon angioplasty for in-stent restenosis
    Thorsten Reffelmann
    Klinik und Poliklinik f ur Innere Medizin B, Universit atsklinik der, Ernst Moritz Arndt Universit at, Greifswald, Friedrich L offler Str 23 a, 17475, Greifswald, Germany
    J Invasive Cardiol 20:E208-9. 2008
  6. ncbi Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Greifswald, Germany
    J Am Coll Cardiol 53:305-8. 2009
  7. ncbi Combination of electrocardiographic and echocardiographic information identifies individuals prone to a progressive increase in left ventricular mass over 5 years
    Thorsten Reffelmann
    aKlinik und Poliklinik für Innere Medizin B, Universitatsklinikum, Ernst Moritz Arndt Universitat Greifswald, Greifswald, Germany
    J Hypertens 27:861-8. 2009
  8. ncbi Phosphodiesterase 5 inhibitors: are they cardioprotective?
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17475 Greifswald, Germany
    Cardiovasc Res 83:204-12. 2009
  9. ncbi Intracoronary blood- or bone marrow-derived cell transplantation in patients with ischemic heart disease
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17475 Greifswald, Germany
    Regen Med 4:709-19. 2009
  10. ncbi Urinary albumin excretion, even within the normal range, predicts an increase in left ventricular mass over the following 5 years
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, 17487 Greifswald, Germany
    Kidney Int 77:1115-22. 2010

Detail Information

Publications39

  1. ncbi Low serum magnesium concentrations predict cardiovascular and all-cause mortality
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17487 Greifswald, Germany
    Atherosclerosis 219:280-4. 2011
    ..As left ventricular hypertrophy has significant prognostic implications, we hypothesized that serum Mg(++) levels are associated with cardiovascular mortality...
  2. ncbi Images in cardiovascular medicine. Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy
    Thorsten Reffelmann
    Medical Clinic I, Department of Cardiology, University Hospital Aachen, , Pauwelsstrasse 30, 52057 Aachen, Germany
    Circulation 114:e357-8. 2006
  3. ncbi Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B Ernst Moritz Arndt Universität Greifswald, Greifswald, Germany
    Expert Opin Pharmacother 8:965-74. 2007
    ..Importantly, any drug serving as a nitric oxide donor is contraindicated in combination with vardenafil...
  4. ncbi The cardiovascular safety of tadalafil
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinik der, Ernst Moritz Arndt Universitat Greifswald, Friedrich Löffler Str 23 a, 17475 Greifswald, Germany
    Expert Opin Drug Saf 7:43-52. 2008
    ....
  5. ncbi Unintentional extraction of a coronary stent deployed 4 months earlier during cutting-balloon angioplasty for in-stent restenosis
    Thorsten Reffelmann
    Klinik und Poliklinik f ur Innere Medizin B, Universit atsklinik der, Ernst Moritz Arndt Universit at, Greifswald, Friedrich L offler Str 23 a, 17475, Greifswald, Germany
    J Invasive Cardiol 20:E208-9. 2008
    ..Retrospective analysis of the stent implantation procedure 4 months prior revealed complete stent expansion and closely matched stent and vessel dimensions as assessed by angiographic criteria...
  6. ncbi Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Greifswald, Germany
    J Am Coll Cardiol 53:305-8. 2009
    ....
  7. ncbi Combination of electrocardiographic and echocardiographic information identifies individuals prone to a progressive increase in left ventricular mass over 5 years
    Thorsten Reffelmann
    aKlinik und Poliklinik für Innere Medizin B, Universitatsklinikum, Ernst Moritz Arndt Universitat Greifswald, Greifswald, Germany
    J Hypertens 27:861-8. 2009
    ..We assessed whether the relationship between electrocardiographic and echocardiographic information on left ventricular hypertrophy predicts the development of left ventricular mass over 5 years...
  8. ncbi Phosphodiesterase 5 inhibitors: are they cardioprotective?
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17475 Greifswald, Germany
    Cardiovasc Res 83:204-12. 2009
    ..In this review, we discuss mechanisms, signalling pathways, and experimental limitations and touch on considerations for translation into potentially useful applications in the clinical arena...
  9. ncbi Intracoronary blood- or bone marrow-derived cell transplantation in patients with ischemic heart disease
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17475 Greifswald, Germany
    Regen Med 4:709-19. 2009
    ..Moreover, the potential effects of cell therapy must be evaluated as treatment options additive to established therapeutic strategies...
  10. ncbi Urinary albumin excretion, even within the normal range, predicts an increase in left ventricular mass over the following 5 years
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, 17487 Greifswald, Germany
    Kidney Int 77:1115-22. 2010
    ..Our study found that the urinary albumin-to-creatinine ratio, even below the current threshold for definition of microalbuminuria, is significantly associated with increased left ventricular mass...
  11. ncbi Ranolazine: an anti-anginal drug with further therapeutic potential
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Strasse 23a, Greifswald, Germany
    Expert Rev Cardiovasc Ther 8:319-29. 2010
    ..In this review we discuss the pharmacological profile of ranolazine and discuss the current and potential future applications in cardiovascular disease for this drug...
  12. ncbi Mild renal dysfunction as a non-traditional cardiovascular risk factor?-Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17487 Greifswald, Germany
    Atherosclerosis 211:660-6. 2010
    ..The purpose of this study was to evaluate whether early stages of renal dysfunction are associated with flow-mediated vasodilatation, as an early marker of the atherosclerotic disease process...
  13. ncbi Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease
    T Reffelmann
    Medizinische Klinik I, University Hospital, Rheinisch Westfälische Technische Hochschule RWTH, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Heart 87:54-60. 2002
    ..To investigate whether blood flow in normal and post-stenotic coronary arteries is altered by therapeutic doses of the sulfonylurea agent glibenclamide...
  14. ncbi Low serum magnesium concentrations predict increase in left ventricular mass over 5 years independently of common cardiovascular risk factors
    Thorsten Reffelmann
    Klinik und Poliklinik für Innere Medizin B, Universitätsklinikum der Ernst Moritz Arndt Universität Greifswald, Friedrich Löffler Str 23 a, 17487 Greifswald, Germany
    Atherosclerosis 213:563-9. 2010
    ..Left ventricular hypertrophy (LVH) is a significant predictor of adverse cardiovascular events. Experimental studies suggest a pathophysiological role of magnesium (Mg(2+)) in the development of arterial hypertension and LVH...
  15. ncbi Blood supply of the graft after cellular cardiomyoplasty
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Division of Cardiology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90017 2395, USA
    Regen Med 5:777-86. 2010
    ..This review summarizes research that specifically studied the occurrence, magnitude and mechanisms of enhanced myocardial blood supply after cellular cardiomyoplasty...
  16. ncbi Clinical and angiographic predictors of recurrent restenosis after percutaneous transluminal rotational atherectomy for treatment of diffuse in-stent restenosis
    J vom Dahl
    Department of Cardiology, University Hospital, University of Technology, Aachen, Germany
    Am J Cardiol 83:862-7. 1999
    ..PTRA resulted in an acceptable recurrent restenosis rate in short and modestly diffuse lesion, whereas the restenosis rate in very long lesions remains high despite debulking...
  17. ncbi Mechanisms of acute lumen gain and recurrent restenosis after rotational atherectomy of diffuse in-stent restenosis: a quantitative angiographic and intravascular ultrasound study
    P W Radke
    Medical Clinic I, RWTH University Hospital, Aachen, Germany
    J Am Coll Cardiol 34:33-9. 1999
    ....
  18. ncbi Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Cardiovasc Res 59:441-9. 2003
    ..CONCLUSIONS: Sildenafil reduced cardiac pre- and afterload, and parameters of left ventricular contractility. Myocardial necrosis and microvascular dysfunction were neither exacerbated nor attenuated...
  19. ncbi Activation of ATP-sensitive potassium channels in hypoxic cardiac failure is not mediated by adenosine-1 receptors in the isolated rat heart
    T Reffelmann
    Medical Clinic I, University Hospital, , Germany
    J Cardiovasc Pharmacol Ther 6:189-200. 2001
    ..These effects seem to be independent of the A-1 receptor in this model...
  20. ncbi Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Expert Opin Drug Saf 4:531-40. 2005
    ..When a stable cardiac condition can be achieved (low risk group), oral treatment for erectile dysfunction may be appropriate...
  21. ncbi Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage?
    Thorsten Reffelmann
    Heart Institute, Good Samaritan Hospital, and Cardiovascular Division, University of Southern California, Los Angeles, California 90017-2395, USA
    Am J Physiol Heart Circ Physiol 284:H1134-41. 2003
    ..Because size and spatial distribution of no reflow and myocardial necrosis remained closely coupled with independent cardioprotective interventions, a potential causal connection between microvascular and myocardial salvage is discussed...
  22. ncbi Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, University of Southern California, Los Angeles, CA 90017-2395, USA
    Circulation 108:239-44. 2003
  23. ncbi Cardiovascular effects of phosphodiesterase 5 inhibitors
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, University of Southern California, Keck School of Medicine, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Curr Pharm Des 12:3485-94. 2006
    ..S. in June 2005. Recently, direct cardioprotective effects were described in animal research, resembling preconditioning-like effects, which may, under certain conditions, also be applicable in clinical research...
  24. ncbi Sexual function in hypertensive patients receiving treatment
    Thorsten Reffelmann
    University of Southern California, The Heart Institute, Good Samaritan Hospital, Division of Cardiovascular Medicine, Keck School of Medicine, Los Angeles, CA 90017-2395, USA
    Vasc Health Risk Manag 2:447-55. 2006
    ..Also, a-adrenoceptor blockers, such as doxazosin, terazosin and tamsulosin, should only be combined with phosphodiesterase 5 inhibitors with special caution and close monitoring of blood pressure...
  25. ncbi Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, California 90017-2395, USA
    Am J Physiol Heart Circ Physiol 282:H766-72. 2002
    ..Thus microvascular reperfusion injury led to a striking decrease in RMBF within the first 2 h of reperfusion, with infarct size as the major determinant of reflow at a given time point of reperfusion...
  26. ncbi A novel minimal-invasive model of chronic myocardial infarction in swine
    Thorsten Reffelmann
    Medizinische Klinik I, University Hospital, , Germany
    Coron Artery Dis 15:7-12. 2004
    ..It avoids major surgery and thoracotomy and does not require balloon inflation or intracoronary injection of thrombotic or chemical agents...
  27. ncbi Transplantation of neonatal cardiomyocytes after permanent coronary artery occlusion increases regional blood flow of infarcted myocardium
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, CA 90017-2395, Los Angeles, USA
    J Mol Cell Cardiol 35:607-13. 2003
    ..CONCLUSIONS: Transplantation of neonatal cardiomyocytes induced neo-angiogenesis in zones of successful cell engraftment within the scar, which effectively enhanced tissue perfusion...
  28. ncbi The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Dept. of Cardiology, Division of Cardiovascular Medicine at Keck School of Medicine, University of Southern California, 1225 Wilshire Boulevard, Los Angeles (CA) 90017, USA
    Basic Res Cardiol 101:359-72. 2006
    ....
  29. ncbi No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Blvd, Los Angeles, CA 90017, USA
    Circulation 108:2911-7. 2003
    ....
  30. ncbi Transplantation of fetal cardiomyocytes into infarcted rat hearts results in long-term functional improvement
    Erik Skobel
    Medizinische Klinik I and Department of Molecular Cardiovascular Research, Department of Cardiology, University Hospital Aachen, Aachen, Germany
    Tissue Eng 10:849-64. 2004
    ....
  31. ncbi Microvascular alterations after temporary coronary artery occlusion: the no-reflow phenomenon
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, CA 90017-2395, USA
    J Cardiovasc Pharmacol Ther 9:163-72. 2004
    ..As a consequence, improving tissue perfusion might concomitantly improve the healing process, which may provide the pathoanatomic basis for prognostic implications of no-reflow...
  32. ncbi Comparison of rotational with conventional coronary angiography
    Klaus Empen
    Department of Cardiology, Ernst Moritz Arndt University, Greifswald, Germany
    Am Heart J 160:552-63. 2010
    ..Rotation of the C-arm during CA could provide similar diagnostic accuracy and lower radiation exposure and contrast medium consumption...
  33. ncbi Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, California 90017-2395, USA
    Am J Physiol Heart Circ Physiol 283:H1099-107. 2002
    ..06 +/- 0.01 ml x min(-1) x g(-1)). The development of macroscopic hemorrhage lagged behind no reflow, was closely correlated with it, and may be the consequence of microvascular damage...
  34. ncbi The "no-reflow" phenomenon: basic science and clinical correlates
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017-2395, USA
    Heart 87:162-8. 2002
  35. ncbi Transthoracic echocardiography in rats. Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) in comparison with Wistar rats during
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Basic Res Cardiol 98:275-84. 2003
    ..The data might be used to choose the most sensitive parameters, and to estimate sample size for echocardiographic investigations in rats...
  36. ncbi Effects of adenosine and verapamil on anatomic no-reflow in a rabbit model of coronary artery occlusion and reperfusion
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, University of Southern California, Los Angeles, CA 90017-2395, USA
    J Cardiovasc Pharmacol 43:580-8. 2004
    ....
  37. ncbi Association of serum IGF1 with endothelial function: results from the population-based study of health in Pomerania
    Klaus Empen
    Department of Cardiology, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany
    Eur J Endocrinol 163:617-23. 2010
    ..The aim of this study was to analyze the association between serum IGF1 as well as IGF-binding protein 3 (IGFBP3) levels and endothelial function measured by flow-mediated dilation (FMD)...
  38. ncbi Cellular cardiomyoplasty--cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure?
    Thorsten Reffelmann
    The Heart Institute, Good Samaritan Hospital, Cardiovascular Division, University of Southern California, 1225 Wilshire Boulevard, 90017-2395, Los Angeles, CA, USA
    Cardiovasc Res 58:358-68. 2003
  39. ncbi Cardioprotection by Carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart
    Ernst R Schwarz
    Department of Cardiology, RWTH University Hospital Aachen, Germany
    J Cardiovasc Pharmacol Ther 8:207-15. 2003
    ..In addition to its beta-adrenergic receptor blockage, antiapoptotic effects have been demonstrated in experimental animals...